Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026. Here’s what investors need to know.Aurinia Pharmaceuticals stock is feeling bearish pressure. What’s pressuring AUPH stock?Lupkynis Sales Drive Full-Year GrowthThe company reported fourth-quarter 2025 adjusted earnings of 26 cents a share, beating analysts' consensus of 22 cents and surging from one cent a ...

Aurinia Pharmaceuticals (NasdaqGM:AUPH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsGreg Keenan - Chief Medical OfficerJoe Miller - CFOPeter Greenleaf - President and CEOSahil Dhingra - Senior Equity Research AssociateWill Sawicki - AssociateConference Call ParticipantsArthur He - AnalystDavid Martin - AnalystFarzin Haque - Senior Vice President and Biotechnology Equity Research AnalystOlivia Brayer - Senior Equity AnalystOperatorGood morning. Welcome to the Aurinia Pharmaceutica ...

Aurinia Pharmaceuticals (NasdaqGM:AUPH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsGreg Keenan - Chief Medical OfficerJoe Miller - CFOPeter Greenleaf - President and CEOSahil Dhingra - Senior Equity Research AssociateWill Sawicki - AssociateConference Call ParticipantsArthur He - AnalystDavid Martin - AnalystFarzin Haque - Senior Vice President and Biotechnology Equity Research AnalystOlivia Brayer - Senior Equity AnalystOperatorGood morning. Welcome to the Aurinia Pharmaceutica ...

Aurinia Pharmaceuticals (NasdaqGM:AUPH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker6Good morning. Welcome to the Aurinia Pharmaceuticals fourth quarter and full year 2025 conference call. Please be advised that a Q&A session will follow Aurinia's prepared remarks. We ask you please ask 1 question and 1 follow-up, then return to the queue. I'll now turn the call over to Peter Greenleaf, President and Chief Executive Officer of Aurinia. Peter, please go ahead.Speaker7Good morning. We want to t ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.79%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.16 per share when it actually produced earnings of $0.23, delivering a surprise of +43.75%.Over the last fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ Form 10-K ___________________________________________________________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______ ...

Core Viewpoint - Aurinia Pharmaceuticals Inc. will report its financial results for the three and twelve months ended December 31, 2025, and provide a business update on February 26, 2026 [1] Financial Reporting - The financial results will cover both the three-month and twelve-month periods ending December 31, 2025 [1] - A webcast and conference call will be hosted by the management team on February 26, 2026, at 8:30 a.m. ET [1] Conference Call Details - The conference call can be accessed by dialing 877-407-8029 or +1 201-689-8029 [1] - A link to the webcast is provided for participants [1]

Company Performance - Aurinia Pharmaceuticals (AUPH) has returned approximately 81.2% since the start of the calendar year, significantly outperforming the average gain of 8.2% for Medical stocks [4] - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [4] - Aurinia Pharmaceuticals is currently ranked 2 (Buy) in the Zacks Rank system, which emphasizes earnings estimates and revisions [3] Industry Comparison - Aurinia Pharmaceuticals is part of the Medical - Drugs industry, which includes 146 stocks and is currently ranked 70 in the Zacks Industry Rank, with an average gain of 9.4% this year [6] - In contrast, Cardinal Health (CAH), another Medical stock, has returned 75.5% since the beginning of the year and is part of the Medical - Dental Supplies industry, which is ranked 102 and has gained 13.3% [5][6] - The Medical group, which includes Aurinia Pharmaceuticals, is currently ranked 6 within the Zacks Sector Rank, which evaluates 16 different sector groups [2]

Core Insights - Jefferies recently released a report on the outlook for the U.S. biotech industry in 2026, focusing on preferred investment targets, undervalued potential companies, and potential acquisition opportunities. The report highlights that the biotech sector will see multiple key clinical trial data disclosures, new drug approvals, and policy developments in 2026, with companies in niche segments likely to achieve value re-evaluation through technological breakthroughs and commercialization progress [1]. Preferred Investment Targets - Jefferies identified six core recommended companies for 2026 based on market catalysts and valuation potential: - **Dianthus Therapeutics**: Target price of $66, focusing on the drug claseprubart for various neuromuscular diseases, with peak revenue estimated at $2 billion. Key milestones include mid-analysis of Phase III trials for CIDP and initiation of trials for gMG in 2026 [1]. - **Taysha Gene Therapies**: Target price of $11, with TSHA-102 for Rett syndrome showing significant market potential (peak revenue of $2 billion). Phase III trial data is expected by the end of 2026 [2]. - **Tyra Biosciences**: Target price of $32, with the drug dabogratinib showing disruptive potential in bladder cancer and achondroplasia. Key data is expected next year [2]. - **Tango Therapeutics**: Target price of $14, exploring a combination therapy for pancreatic cancer with expected data release in mid-2026 [2]. - **ORIC Pharmaceuticals**: Target price of $23, with two key assets targeting prostate cancer and lung cancer. Key data updates are anticipated next year [3]. - **Solid Biosciences**: Target price of $15, focusing on gene therapy for Duchenne muscular dystrophy, with critical meetings with the FDA planned for 2026 [3]. Undervalued Companies - The report highlights seven undervalued companies with significant catalysts and potential for value re-evaluation: - **Ultragenyx Pharmaceutical**: Target price of $114, with a current undervalued stock price. Key catalysts include Phase III data for setrusumab expected in late 2025 to early 2026, potentially driving a 100% stock price increase [4]. - **Beam Therapeutics**: Target price of $41, focusing on gene editing with promising data updates expected in early 2026 [5]. - **Aurinia Pharmaceuticals**: Target price of $21, with steady growth in lupus nephritis treatment and new drug development expected to drive growth [5]. - **Kodiak Sciences**: Target price of $39, with three Phase III trial data readouts expected in 2026 [6]. - **Intellia Therapeutics**: Target price of $45, with key data for hereditary angioedema therapy expected in mid-2026 [6]. - **Compass Therapeutics**: Target price of $8, with upcoming data for cholangiocarcinoma therapy expected in early 2026 [6]. - **KalVista Pharmaceuticals**: Target price of $38, with a first-in-class oral treatment for hereditary angioedema expected to drive rapid growth [7]. Potential Acquisition Targets - Jefferies identified five companies that may become acquisition targets in 2026 due to their unique assets or market positions: - **Arrowhead Pharmaceuticals**: Strong RNAi product line in cardiovascular metabolism and new obesity targets [8]. - **Celcuity**: Unique efficacy of gedatolisib in PIK3CA wild-type breast cancer [8]. - **ORIC Pharmaceuticals**: High-value prostate and lung cancer projects [8]. - **Travere Therapeutics**: Potential market expansion in rare kidney diseases if FSGS indication is approved [8]. - **KalVista Pharmaceuticals**: First-mover advantage and strong growth in oral HAE treatment [8].

Core Insights - Aurinia Pharmaceuticals Inc. (AUPH) has experienced significant developments recently, including continued growth in its drug Lupkynis, the approval of a competitor's drug for lupus nephritis, and a request for information from the FDA [1] Company Developments - The earnings update from Aurinia Pharmaceuticals indicates ongoing growth in the sales of Lupkynis, which is a positive sign for the company's financial health [1] - A competitor's drug has received approval for lupus nephritis, which may impact Aurinia's market position and competitive landscape [1] - The FDA has requested additional information, which could influence the regulatory pathway for Aurinia's products [1]